Editas Medicine, Inc. (NASDAQ:EDIT) Traded Lower Than Its 50 Day Moving AverageModern ReadersCRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prevotella… Continue reading
Stem Cell Media Market Report 2017-2022 by Players, Regions, Types & ApplicationsMedgadget (blog)QY Research Groups has published its new and latest market report based on thorough research on the United States Stem Cell Media Market. This detailed… Continue reading
Stem Cell Media Market Report 2017-2022 by Players, Regions, Types & ApplicationsMedgadget (blog)QY Research Groups has published its new and latest market report based on thorough research on the United States Stem Cell Media Market. This detailed… Continue reading
Editas Medicine, Inc. (NASDAQ:EDIT) Stock Closed -0.3% Below Its 50 Day Moving AverageFirst News 24CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prev… Continue reading
FierceBiotechRocket to merge with Inotek to bag Nasdaq listing, plots gene therapy trialsFierceBiotechRocket Pharmaceuticals has landed a Nasdaq listing through a reverse merger. The deal will see the low-profile gene therapy startup merge with flounde… Continue reading
Alternative CRISPR system is less specific, more robustPhys.OrgThe genetic tool adept at line-by-line gene editing, CRISPR, has revolutionized the ability of scientists to manipulate genes for experimental, and perhaps someday therapeutic, purposes. Bu… Continue reading
ALS News TodayHuman Skin Cells Successfully Converted into Motor NeuronsALS News TodayScientists have discovered how adult skin cells can be converted into motor neurons without transitioning them through a stem cell state. The findings promise to help… Continue reading
Phys.OrgUsing synthetic biology for chlamydia vaccinesPhys.OrgA multidisciplinary scientific team at Lawrence Livermore National Laboratory (LLNL) has made significant advances in developing a vaccine for chlamydia using synthetic biology, sponsored by… Continue reading